FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Alfredo Falcone, Monica Ronzoni et al.|The Lancet Oncology|2015Cited by 1.1k
Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast CancerWilliam C. Dooley, Eileen B. King, Britt‐Marie Ljung et al.|JNCI Journal of the National Cancer Institute|2001Cited by 275
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective studyGrazia Arpino, Sabino De Placido, Andrea Michelotti et al.|Journal of Cancer Research and Clinical Oncology|2015Cited by 15
Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)Michelino De Laurentiis, Grazia Arpino, Luca Malorni et al.|Cancer Research|2020Cited by 6